Lifeboat Foundation

“In a breakthrough study published on February 19th in Nature Biomedical Engineering, researchers connected neural dust implants reduced to 1.7 cubic millimeters to rat sciatic nerves. The implanted device, called the StimDust system, consisted of very few components, which will be scaled down for future applications. A piezoceramic ultrasonic transducer generated power allowing for wireless communication and stimulation. A capacitor stored any excess energy generated from ultrasonic beams. Bipolar stimulating electrodes directly interfaced with the nerve while a cuff attached to a small circuit-board allowed the device to adhere physically to the nerve. These components were sufficient to generate or record nerve-impulses. In anesthetized rodents, they elicited muscular contractions with the StimDust system.”

While Neuralink, Elon Musk’s startup-venture focused on creating a brain-computer interface, garners lots of coverage in the biotechnology space, other bioelectronics ventures continue innovating in this space.

iota Biosciences, a spin-off company from UC Berkley formed in 2017, made news two years ago by securing $15 million in Series A funding and again last year announcing a partnership with Astellas Pharma Inc. Bolstered by studies in rodents, iota Biosciences advances towards their vision. In a press release on their partnership, founders Jose Carmena and Michel Maharbiz commented:

Continue reading “Neural Dust: Millimeter-Sized Brain Stimulators” »

SpaceX launched its first crewed mission to ISS in May this year. The company demonstrated its spacecraft is safe and reliable to carry humans to space and back. Axiom’s space tourist mission with SpaceX is scheduled to be a 10-day journey that will launch civilians aboard Crew Dragon to the space station atop a Falcon 9 rocket. The space tourists will stay at ISS for 8 days, where they will experience microgravity and amazing views of our planet.

SpaceX’s first private civilian flight will carry three Axiom customers who will fly alongside former NASA Astronaut Michael Lopez-Alegria, he will be commander during the mission. Earlier this year, NASA and SpaceX announced Hollywood actor Tom Cruise will film a movie at the space station and fly aboard Crew Dragon. Then, reports surfaced about Cruise and his film production agency working with Axiom is responsible for providing ‘training, mission planning, hardware development, life support, medical support, crew provisions, hardware and safety certifications, on-orbit operations and overall mission management.’ However, Axiom has not officially disclosed who their private passengers will be on their first mission in collaboration with SpaceX.

Rock-climb without fear. Play a symphony in your head. See radar with superhuman vision. Discover the nature of consciousness. Cure blindness, paralysis, deafness, and mental illness. Those are just a few of the applications that Elon Musk and employees at his four-year-old neuroscience company Neuralink believe electronic brain-computer interfaces will one day bring about.

None of these advances are close at hand, and some are unlikely to ever come about. But in a “product update” streamed over YouTube on Friday, Musk, also the founder of SpaceX and Tesla Motors, joined staffers wearing black masks to discuss the company’s work toward an affordable, reliable brain implant that Musk believes billions of consumers will clamor for in the future.

Continue reading “Elon Musk’s Neuralink is neuroscience theater” »

If this works out… Thank you llamas! 😃

An antibody produced by llamas seems particularly effective at neutralizing a key protein of the novel coronavirus.

At the Cronin Lab at the University of Glasgow chemists developed a robotic chemist called a “chemputer” that turns words into molecules.

U.S. company can keep hosting vast coronavirus-related project but must protect French citizens’ health data from American government, court rules.

A French court has ruled that Microsoft Corp. can continue hosting a government-run project aggregating citizens’ anonymous health data to use for AI-based research, but must guarantee no data will be sent to the U.S. or be shared with American intelligence authorities.

The ruling, handed down last week, contradicts the stance of France’s data protection authority, which told the court this month that any U.S. cloud provider could be forced to comply with U.S. surveillance laws and should therefore not be allowed to host sensitive health data. The regulator’s opinion could provide clues for other companies handling such data, legal experts say.

Continue reading “French Court Asks Microsoft for Safeguards Against U.S. Surveillance of Health Data” »

In the 2013 science fiction film “Elysium” starring Matt Damon, Earth’s wealthiest 0.01% move to the ultimate gated community, a luxurious orbiting space colony, leaving a poverty-stricken humanity to fend for themselves on a ravaged planet.

Interestingly, it is indeed some of today’s 0.1% who are leading the way into space to build communities beyond Earth. However, quite the opposite of the movie, their goals are of the highest order, from democratizing access to space by lowering costs, to creating new products and ideas, to helping save the planet and opening space to future generations.

Yet, given the effects of the coronavirus pandemic, social justice and green movements, even as entrepreneurs like Elon Musk, Jeff Bezos and Richard Branson spend billions to support a human breakout into space, there is a backlash building that holds these projects as icons of extravagance — even as their work may help save the Earth. This is the “Elysium effect.”

Such superbugs may also be contributing to the tens of thousands of excess deaths occurring during the COVID-19 era. Hence why doctors around the world are sounding the alarm.

Doctors worry that a dangerous yeast, which can colonize a person’s skin without generating symptoms, is rising due to medical centers being overrun.

A team of researchers at Duke University have developed an imaging technology for tagging structures at a cellular level that overcomes the shortcomings of existing antibody-based techniques. Immunofluorescence imaging is a key part of the cell biologist’s toolbox, in which a fluorescent ‘flare’ attached to an antibody allows them to visualize the presence of specific target proteins in cell or tissue samples. The issue is that this specificity isn’t always 100 percent — sometimes the antibodies bind to other closely related proteins as well, making it difficult to interpret the results.

Duke’s cell biology chair Scott Soderling has led a team that developed Homology-independent Universal Genome Engineering (HiUGE), an innovation that uses gene-editing technology to rise above the shortcomings of traditional commercial antibodies for imaging.

Continue reading “New CRISPR-Based Imaging Tool Is Going to Be HiUGE” »